Ophthalmic Drugs Conference 2018

SMi Group26 - 27 November 2018, London, UK.
As the global population ages, the incidence of ophthalmic disorders continues to grow, and thus the interest of pharmaceutical and biotech companies is increasingly focused towards innovation of novel approaches for the development of ophthalmic drugs, driving the growth of the global ophthalmic drug market, which is projected to reach £30 billion by 2023.

Building on last year's success, this must-attend conference will bring together industry experts to discuss and analyse the latest advancements and challenges within ophthalmic drug development and delivery. Some notable areas of interest have been neuroprotection in ophthalmology, advancements in gene therapy, AMD clinical trial updates, and novel approaches for delivery of ocular drugs. The two-day event will also feature two interactive, half-day post-conference workshops on 28th November 2018, led by twoXAR and Aston University

This Year's Agenda Highlights Include

  • Discover recent advances in the treatment of glaucoma
  • Gain insight into the first FDA-approved gene therapy, developed for the treatment of inherited retinal dystrophy
  • Discuss case studies on novel non-invasive and site-specific drug delivery strategies
  • Examine the applications of artificial intelligence in drug discovery
  • Explore use of biomarkers and surrogate end-points from a regulatory perspective

Chairs for 2018

  • Mitchell de long, Vice President, Chemistry, Aerie Pharmaceuticals
  • Naj Sharif, Executive Director and Head, Global Alliances & External Research, Santen

Key Speakers

  • Majid Anderesi, Associate Group Clinical Director, Ophthalmology, Roche
  • Caroline Barelle, CEO, Elasmogen
  • Victor Chong, Global Head of Ophthalmology, Boehringer Ingelheim
  • Daniel Chung, Clinical Ophthalmic Lead, Spark Therapeutics
  • Aniz Girach, Chief Medical Officer, Nightstar Therapeutics
  • Peter Morgan-Warren, Medical Assessor, Licensing Division, MHRA
  • David Silverman, Clinical Director, Ophthalmology, Roche

View the full agenda online: www.ophthalmicdrugs.com/wpn

Early-bird rates

  • Register by 29th June and save £300
  • Register by 28th September and save £200
  • Register by 31st October and save £100

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...